Separate terms with OR to return results that match either term.
 
Clear All
9,752 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
55150-0384-01 55150-0384 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular, Soft Tissue July 5, 2022 In Use
43598-0142-06 43598-0142 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 9, 2023 In Use
55150-0393-01 55150-0393 AZACITIDINE AZACITIDINE 100.0 mg/4mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jan. 3, 2023 In Use
61703-0124-40 61703-0124 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intramuscular, Intrathecal, Intravenous, Subcutaneous Jan. 9, 2023 In Use
60760-0654-10 60760-0654 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 22, 2022 In Use
62332-0650-05 62332-0650 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 22, 2022 In Use
63629-9530-01 63629-9530 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 12, 2022 In Use
63187-0256-15 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use
63187-0256-30 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 1, 2017 In Use
63187-0256-10 63187-0256 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 28, 2022 In Use

Found 9,752 results in 12 milliseconds — Export these results